Overview

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation

Status:
Unknown status

Trial end date:
2018-06-01

Target enrollment:

Participant gender:

Summary

Decitabine can up-regulate a series of immune associated proteins, including cancer testis antigens (CTA), major histocompatibility complex (MHC), co-stimulatory molecules and adhesion molecules, which suggests a potential benefit for a following adoptive T cell therapy. In addition, decitabine induce FOXP3 expression in CD4+ T cells and convert CD4+ T cells into T regulatory cells(Tregs). As a result, Graft versus host disease(GVHD) can be reduced by treatment of decitabine.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Chinese PLA General Hospital

Collaborator:

Navy General Hospital, Beijing

Treatments:

Decitabine